Cajuina 2 is a 370.5MW onshore wind power project. It is planned in Rio Grande do Norte, Brazil. According to GlobalData, who tracks and profiles over 170,000 power plants worldwide, the project is currently at the under construction stage. It will be developed in a single phase. The project construction is likely to commence in 2022 and is expected to enter into commercial operation in 2023. Buy the profile here.
Description
The project is being developed and currently owned by AES Brasil Energia. The company has a stake of 100%.
Development status
The project construction is expected to commence from 2022. Subsequent to that it will enter into commercial operation by 2023.
Contractors involved
Nordex will be the turbine supplier for the wind power project. The company is expected to provide 65 units of N163/5.X turbines, each with 5.7MW nameplate capacity.
Nordex is expected to perform operations and maintenance for the wind power project for a period of 5 years.
The wind power project will consists of Concrete towers to be supplied Nordex. These towers will be around 120m high.
For more details on Cajuina 2, buy the profile here.
About AES Brasil Energia
AES Brasil Energia SA (AES Brasil Energia), is a subsidiary of AES Corp, operates as a power generation company. The company utilizes hydroelectric power plants along the rivers in the northwestern and central regions to generate distributable power. The company operates as concessionaire for the use of public assets to generate and trade electric power as independent power producer. Its power generation facilities include hydroelectric power plants and small hydroelectric plants. Its plants are located in Tiete, Grande, Pardo and Mogi-Guacu, in Sao Paulo, Brazil. AES Tiete Energia is headquartered in Sao Paulo, Brazil.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.